Protective effects of tumor necrosis factor in murine hematopoiesis during cycle-specific cytotoxic chemotherapy

Tumor necrosis factor (TNF) is a pleiotropic cytokine which exerts a wide range of effects when administered in vivo. Using a murine model, we have investigated the effect of pretreatment with 1 microgram (2.6 x 10(4) units) per mouse of recombinant murine TNF-alpha on hematopoietic recovery followi...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 1990-07, Vol.50 (14), p.4216-4220
Main Authors: SLOÊRDAL, L, WARREN, D. J, MOORE, M. A. S
Format: Article
Language:English
Subjects:
Animals
Biological and medical sciences
Bone Marrow - drug effects
Bone Marrow - pathology
Colony-Forming Units Assay
Cyclophosphamide - toxicity
Drug toxicity and drugs side effects treatment
Erythrocyte Count - drug effects
Fluorouracil - toxicity
Hematopoiesis - drug effects
Hematopoietic Stem Cells - drug effects
Leukocyte Count - drug effects
Medical sciences
Methotrexate - toxicity
Mice
Mice, Inbred BALB C
Neutrophils - cytology
Neutrophils - drug effects
Pharmacology. Drug treatments
Platelet Count - drug effects
Recombinant Proteins - pharmacology
Toxicity: blood
Tumor Necrosis Factor-alpha - pharmacology
Vinblastine - toxicity
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tumor necrosis factor (TNF) is a pleiotropic cytokine which exerts a wide range of effects when administered in vivo. Using a murine model, we have investigated the effect of pretreatment with 1 microgram (2.6 x 10(4) units) per mouse of recombinant murine TNF-alpha on hematopoietic recovery following administration of cyclophosphamide, 5-fluorouracil, methotrexate, or vinblastine. TNF pretreatment results in enhanced regeneration of circulating neutrophils and hematopoietic progenitors, as measured by in vivo and in vitro assays, in animals given cycle-specific chemotherapeutic agents. The results may suggest that TNF affects cycle kinetics in hematopoietic progenitor cell populations, thus making these cells less prone to the cytocidal effects of the chemotherapeutic agents. As myeloablation is a frequent and often critical side effect following cancer treatment, these findings may have clinical implications.
ISSN:0008-5472
1538-7445